Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News RXi Pharmaceuticals Corp RXII

Healthcare Biotechnology
"RXi Pharmaceuticals Corp is a clinical-stage RNAi company developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which address significant unmet medical needs."

Recent & Breaking News (NDAQ:RXII)

RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants

PR Newswire May 27, 2015

RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock

PR Newswire May 27, 2015

RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference

PR Newswire May 26, 2015

RXi Pharmaceuticals Reports First Quarter 2015 Financial Results and Business Highlights

PR Newswire May 13, 2015

RXi Pharmaceuticals Presented Promising New Data with Self-delivering RNAi Compounds Targeting Tyrosinase and Collagenase

PR Newswire May 11, 2015

RXi Pharmaceuticals to Webcast First Quarter 2015 Financial Results on Wednesday, May 13, 2015

PR Newswire April 29, 2015

RXi Pharmaceuticals Announces Upcoming Presentations at Leading Partnering and Scientific Conferences

PR Newswire April 27, 2015

RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights

PR Newswire March 30, 2015

RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer

PR Newswire March 27, 2015

RXi Pharmaceuticals Reports Positive Advancements in its Dermatology Programs at the Occasion of the 73rd Annual Meeting of the American Academy of Dermatology

PR Newswire March 23, 2015

RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2014 Financial Results on Monday, March 30, 2015

PR Newswire March 16, 2015

RXi Pharmaceuticals to Present at the 73rd Annual Meeting of the American Academy of Dermatology

PR Newswire March 11, 2015

RXi Pharmaceuticals Announces Closing of the Exclusive Global Licensing Agreement to Samcyprone(TM) with Hapten Pharmaceuticals

PR Newswire February 5, 2015

RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Ocular Indications

PR Newswire February 3, 2015

RXi Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference

PR Newswire February 2, 2015

RXi Pharmaceuticals to Present at the 7th Annual Biotech Showcase(TM)

PR Newswire January 5, 2015

RXi Pharmaceuticals Issues Open Letter to Shareholders

PR Newswire December 22, 2014

RXi Pharmaceuticals Expands its Clinical Pipeline with an Exclusive Global License for a Second Phase 2 Clinical Compound

PR Newswire December 19, 2014

RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

PR Newswire December 17, 2014

RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2014

PR Newswire November 13, 2014